Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disoproxil fumarate

China flag thumb

HIV deal in China helps GSK rebuild tattered reputation

Country to receive discounted supplies of HIV drug Tivicay

Gilead Sciences

Gilead files Complera follow-up with FDA

HIV therapy could be approved in the US by the end of this year

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

EU flag

Europe wants scientific advice to become pluralistic

Commission endeavours to create a new science committee and reject a single advisor model

- PMLiVE

GSK shelves ViiV sale as it lays out growth strategy

Firm now bullish on the HIV joint pharma project’s prospects

Choices, choices: the rapidly evolving HIV treatment landscape

The treatment options for HIV in Europe has seen some revolutionary changes

- PMLiVE

Non-profit calls to revoke Sovaldi’s European patent

Doctors of the World says Gilead is “abusing its patent” to impose unsustainable prices

- PMLiVE

Gilead to open London headquarters

Mayor Boris Johnson makes announcement as part of trip to Boston, US

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links